前11月96%QDII正收益 广发中证香港创新药ETF涨87%

Group 1 - In the first 11 months of the year, 626 out of 650 comparable QDII funds saw an increase in net value, representing 96.3% of the total [1] - The innovative pharmaceutical sector has rebounded, leading to significant gains for funds heavily invested in this area, with the top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed A/C, achieving a return of 141.57% [1] - The fund's investment strategy focuses on innovative drugs with global competitiveness and high barriers in the medical equipment sector [1] Group 2 - Nine QDII funds recorded gains exceeding 87% in the first 11 months, with four funds from E Fund Management achieving over 92% returns [2] - The top holdings of these funds include companies like Fuhong Hanlin, Xinda Biopharmaceutical, and Keren Biotech [2] - Other high-performing funds include Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation A and C, and GF CSI Hong Kong Innovative Medicine ETF, with returns of 100.32% and 99.68% respectively [2] Group 3 - The Industrial Bank New Economy Mixed Dollar fund, managed by Zhao Bei, has top holdings including Xinda Biopharmaceutical and Jinfang Pharmaceutical [3] - Funds focused on oil and gas, as well as real estate, have underperformed, particularly those tracking the FTSE Saudi Arabia Index [3] Group 4 - The top 10 QDII funds by performance in the first 11 months include Huatai Fuhong Hong Kong Advantage Selection Mixed A, with a return of 141.57%, and E Fund Global Pharmaceutical Industry Mixed C, with a return of 95.67% [4] - The performance of these funds highlights the strong returns in the pharmaceutical sector compared to other sectors like oil and real estate [4]